Count | |
| 13 | |
| 1 | |
| 3 | |
| 19 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 6 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 5 | |
| 1 | |
| 1 | |
| 8 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 5 | |
| 1 | |
| 14 | |
| 1 | |
| 1 | |
| 2 | |
alpha-Glucosidases/administration & dosage/adverse effects/*antagonists & | 1 |
Promoter Regions (Genetics)/drug effects/genetics/*physiology | 4 |
Promoter Regions (Genetics)/drug effects/genetics/immunology | 1 |
Promoter Regions (Genetics)/drug effects/genetics/physiology | 8 |
Promoter Regions (Genetics)/drug effects/*genetics/physiology | 1 |
Trans-Activation (Genetics)/drug effects/genetics/*physiology | 1 |
Trans-Activation (Genetics)/drug effects/genetics/physiology | 1 |
| 1 | |
| 18 | |
| 5 | |
| 1 | |
Antisense Elements (Genetics)/genetics/metabolism/*pharmacology | 1 |
| 31 | |
| 8 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 5 | |
| 1 | |
| 1 | |
| 2 | |
| 4 | |
| 7 | |
| 1 | |
| 1 | |
| 19 | |
| 1 | |
| 3 | |
| 4 | |
| 5 | |
| 5 | |
| 4 | |
| 1 | |
| 27 | |
| 11 | |
| 2 | |
| 2 | |
| 1 | |
| 11 | |
| 68 | |
| 1 | |
| 5 | |
| 86 | |
| 2 | |
| 1 | |
| 3 | |
| 3 | |
| 86 | |
| 68 | |
| 2 | |
| 1 | |
| 822 | |
| 4 | |
| 2 | |
| 1078 | |
| 1 | |
Trans-Activation (Genetics)/drug effects/*genetics/radiation effects | 1 |
| 3 | |
| 166 | |
| 1 | |
| 225 | |